*In the USA, the licensed doses for Pradaxa are 150 mg BID and 75 mg BID for
the prevention of stroke and systemic embolism in adult patients with non-valvular AF.

References:

  1. Graham DJ et al. Circulation 2015;131:157-164.
  2. Connolly SJ et al. N Engl J Med 2009;361(12):1139–1151.
  3. Connolly SJ et al. N Engl J Med 2010;363(19):1875–1876 (appendix).
  4. Pradaxa Summary of Product Characteristics 2015. Boehringer Ingelheim.